Skip to main content

Arcellx, Inc.

ACLXDelisted Apr 28, 2026
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001786205

Arcellx, Inc. was delisted on Apr 28, 2026; its insiders filed their last Form 4 on Apr 28, 2026; 240 institutions reported holding it in 13F filings for Q1 2026, worth $6.52B in total; Soros Fund Management was the only superinvestor holding it.

Q2 2024 vs. Q1 2024

How the institutions holding Arcellx, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of ACLX: Q1 2024 compared with Q2 2024
MeasureQ1 2024Of which not filed for Q2 2024Q2 2024Change
Holders1831167−15
Shares47.0M38.7K50.2M+3.25M (+6.9%)
Value$3.27B$2.69M$2.77B−$494.3M (−15.1%)

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Arcellx, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Sold out (37)

Institutions that held Arcellx, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Not filed for Q2 2024 yet (1)

Institutions that held Arcellx, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ACLX in Q1 2024 that haven't filed for Q2 2024
InstitutionShares, Q1 2024Value, Q1 2024
Credit Suisse AG38,739$2.69M